Fluoroquinolones are synthetic bactericidal antibiotics that target two essential bacterial enzymes, deoxyribonucleic acid (DNA) gyrase (topoisomerase II) and topoisomerase IV, both of which are required for bacterial DNA replication and cell division. The evolution from first-generation nalidixic acid to the fourth-generation respiratory fluoroquinolones reflects a systematic expansion of antimicrobial spectrum through structural modification, with each generation extending activity toward organisms that earlier agents could not reliably cover.1
All fluoroquinolones share a core bicyclic ring structure derived from 4-quinolone. Addition of a fluorine atom at position 6 and a piperazine ring or other substituent at position 7 of this scaffold yields the fluoroquinolone class, dramatically increasing antibacterial potency and broadening spectrum relative to earlier quinolones. The fluorine atom at C-6 enhances penetration through bacterial outer membranes and increases affinity for the topoisomerase targets, while the C-7 substituent is the primary determinant of spectrum and pharmacokinetic behavior. The carboxyl group at C-3 and the ketone at C-4 are essential for chelation of the magnesium-water bridge that stabilizes the drug-enzyme-DNA ternary complex and are conserved across all active members of the class.12
DNA gyrase is a type II topoisomerase composed of two GyrA and two GyrB subunits that introduces negative supercoils into bacterial DNA to relieve torsional stress generated ahead of advancing replication forks and transcription complexes, a function essential for chromosome compaction and replication. Topoisomerase IV is a homologous enzyme composed of ParC and ParE subunits whose primary function is decatenation of interlinked daughter chromosomes following replication, allowing their segregation into daughter cells. Both enzymes act by transiently cleaving both strands of DNA, passing another DNA segment through the break, and then resealing the break, using adenosine triphosphate (ATP) hydrolysis to drive the reaction. Fluoroquinolones trap these enzymes in a covalent complex with broken DNA, converting them from essential enzymes into cellular poisons that block replication fork progression and generate lethal double-strand DNA breaks.12
The primary intracellular target differs between Gram-negative and Gram-positive bacteria in a clinically relevant way. In Gram-negative organisms such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, DNA gyrase is the primary target and the enzyme against which fluoroquinolones have higher intrinsic affinity; topoisomerase IV is a secondary target. In Gram-positive organisms such as Staphylococcus aureus and Streptococcus pneumoniae, the hierarchy is reversed, with topoisomerase IV serving as the primary target and gyrase as secondary. This difference has direct implications for resistance: a single mutation in the primary target gene reduces susceptibility substantially, while resistance requiring mutation of both targets emerges more slowly. Agents such as moxifloxacin that inhibit both targets with more balanced potency achieve lower minimum inhibitory concentrations against Gram-positive pathogens and suppress resistance emergence more effectively than agents with highly asymmetric target preferences.23
Fluoroquinolone killing is concentration-dependent rather than time-dependent, meaning that the pharmacokinetic-pharmacodynamic (PK-PD) parameter that best predicts bactericidal efficacy and resistance suppression is the area under the concentration-time curve to minimum inhibitory concentration ratio (AUC/MIC), also called the area under the inhibitory curve (AUIC). For Gram-negative pathogens, an AUC/MIC ratio above 125 has been associated with optimal bactericidal outcomes and suppression of resistance emergence in multiple clinical studies; for Gram-positive pathogens, ratios above 30 to 40 are often sufficient given the lower minimum inhibitory concentration (MIC) values these organisms typically exhibit against later-generation fluoroquinolones. A secondary pharmacokinetic target is the peak concentration to MIC ratio (Cmax/MIC), which contributes to rapid bacterial killing in the first hours after administration. These concentration-dependent kinetics distinguish fluoroquinolones from beta-lactams and justify strategies such as once-daily high-dose dosing.34
First-generation fluoroquinolones, represented by nalidixic acid, were narrow-spectrum agents with activity limited primarily to Gram-negative Enterobacteriaceae and were used almost exclusively for uncomplicated urinary tract infection (UTI). They are now largely of historical interest, having been displaced by more active agents with superior pharmacokinetics. Second-generation fluoroquinolones include ciprofloxacin, ofloxacin, and norfloxacin. Ciprofloxacin represented a transformative advance in the class, offering broad Gram-negative coverage including reliable antipseudomonal activity, moderate Gram-positive coverage (adequate for methicillin-susceptible Staphylococcus aureus but inadequate for pneumococcal infections), and activity against atypical intracellular pathogens such as Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. Ciprofloxacin remains the fluoroquinolone of choice for infections due to Pseudomonas aeruginosa and for complicated UTI and pyelonephritis.5
Third-generation fluoroquinolones include levofloxacin, which is the L-isomer of ofloxacin and approximately twice as potent as its parent compound. Levofloxacin extends reliable activity against Streptococcus pneumoniae, including penicillin-resistant strains, while retaining broad Gram-negative coverage comparable to ciprofloxacin, though with modestly less antipseudomonal potency. Levofloxacin became a preferred agent for community-acquired pneumonia (CAP) precisely because it reliably covers both the typical pathogens (Gram-negatives, S. aureus) and atypical organisms in a single agent. Fourth-generation fluoroquinolones include moxifloxacin and gemifloxacin, which achieve the broadest antimicrobial spectrum within the class, with enhanced activity against Gram-positives including pneumococci, sustained atypical organism coverage, and added anaerobic activity compared to earlier generations. Moxifloxacin is the only fluoroquinolone with clinically relevant anaerobic coverage, including activity against many Bacteroides fragilis strains. The trade-off for this expanded Gram-positive and anaerobic spectrum is loss of reliable antipseudomonal activity; moxifloxacin should not be used for infections where Pseudomonas coverage is required.56
Moxifloxacin's expanded Gram-positive and anaerobic coverage is often mistaken as broad-spectrum superiority. Its C-8 methoxy substitution, which confers anaerobic activity and enhanced pneumococcal potency, simultaneously reduces antipseudomonal activity to unreliable levels. Do not use moxifloxacin for pneumonia in patients with risk factors for Pseudomonas aeruginosa infection, including bronchiectasis, cystic fibrosis, prior Pseudomonas isolation, or prolonged steroid use. Ciprofloxacin or levofloxacin at high doses (750 mg daily) are the appropriate fluoroquinolone choices when Pseudomonas coverage is required.
The fluoroquinolones as a class are characterized by excellent oral bioavailability, large volumes of distribution reflecting extensive tissue penetration, and a range of elimination pathways that vary substantially between agents and that determine dosing requirements in renal and hepatic impairment. Their pharmacokinetic profile makes them among the most versatile antibiotics available for oral-to-intravenous (IV) interchange, and understanding the drug interactions that impair their absorption or alter their toxicity profile is essential to safe clinical use.7
Oral bioavailability varies across the class but is high for most agents. Levofloxacin achieves near-complete oral bioavailability of approximately 99%, allowing oral dosing to deliver plasma concentrations essentially equivalent to IV administration at the same dose. Moxifloxacin oral bioavailability approaches 89%, while ciprofloxacin achieves approximately 70 to 85% depending on formulation and co-administration with food. These values support routine oral-to-IV interchange for levofloxacin and moxifloxacin on a one-to-one dose basis, an important cost and access consideration for outpatient step-down therapy. The practical clinical implication is that a patient with a functioning gastrointestinal tract who can tolerate oral medications should in most cases receive the oral formulation rather than IV, as plasma exposures are nearly equivalent and IV access carries its own risks.78
Tissue distribution is a defining pharmacokinetic feature of the fluoroquinolones, all of which achieve volumes of distribution substantially exceeding total body water, indicating extensive tissue penetration. Tissue-to-plasma concentration ratios are particularly favorable in the lungs (where concentrations exceed plasma by two- to fivefold), prostate gland (where ciprofloxacin achieves concentrations several times higher than plasma), bile, and intracellular compartments of macrophages and neutrophils. Intracellular accumulation within phagocytes is clinically relevant for infections caused by obligate or facultative intracellular pathogens such as Legionella, Mycobacterium, Chlamydophila, and Brucella species. Cerebrospinal fluid (CSF) penetration is moderate, generally 10 to 40% of plasma concentrations, insufficient to reliably treat bacterial meningitis but adequate for some central nervous system (CNS) infections in specific contexts. Bone penetration is reasonably good, supporting use of oral fluoroquinolones for osteomyelitis after initial parenteral therapy.78
Elimination pathways differ significantly between agents and must be understood to dose correctly in organ impairment. Ciprofloxacin and levofloxacin are eliminated predominantly by renal excretion of unchanged drug, and both require dose adjustment in patients with reduced creatinine clearance (CrCl). For levofloxacin, the standard approach is to reduce the frequency of dosing rather than reduce each individual dose when CrCl falls below 50 mL/min, in order to maintain peak concentration exposures that drive concentration-dependent killing while reducing accumulation. Moxifloxacin is eliminated primarily by hepatic glucuronide and sulfate conjugation followed by biliary and fecal excretion, with renal elimination accounting for only approximately 20% of total clearance; it does not require dose adjustment in renal impairment but should be used cautiously in severe hepatic impairment. Ciprofloxacin has dual renal and hepatic elimination, undergoing partial hepatic metabolism via CYP1A2 (cytochrome P450 isoform 1A2) in addition to active renal tubular secretion.810
The most clinically important pharmacokinetic drug interaction affecting fluoroquinolones is chelation by polyvalent cations. Aluminum- and magnesium-containing antacids, calcium supplements, iron preparations, zinc-containing multivitamins, and sucralfate all form insoluble complexes with fluoroquinolones in the gastrointestinal lumen, reducing oral absorption by 50 to 90% depending on the agent and the dose of cation. Ciprofloxacin is most severely affected; levofloxacin and moxifloxacin are somewhat less susceptible but still significantly impaired. The interaction is managed by timing: oral fluoroquinolones should be administered at least two hours before or four to six hours after any polyvalent cation-containing product. Dairy products cause modest reductions in ciprofloxacin absorption but are generally not clinically significant for levofloxacin and moxifloxacin. Clinicians must counsel patients explicitly on this interaction because patients commonly take antacids or calcium supplements without connecting them to their antibiotic absorption.910
The electrocardiographic ventricular repolarization interval (QT) is prolonged by all fluoroquinolones to varying degrees, and drug interactions that further prolong QT represent a pharmacodynamic concern with serious clinical consequences. All fluoroquinolones prolong the corrected QT interval (QTc) to some degree through blockade of the cardiac hERG (human ether-a-go-go related gene) potassium channel, which carries the rapid delayed rectifier potassium current (IKr). Co-administration with other QT-prolonging agents, including sodium channel-blocking antiarrhythmics (quinidine, procainamide), potassium channel-blocking antiarrhythmics (amiodarone, sotalol, dofetilide), antipsychotics (haloperidol, ziprasidone, quetiapine), and certain antiemetics (ondansetron at higher doses), creates additive QTc prolongation with risk of torsades de pointes (TdP). Moxifloxacin carries the greatest QTc prolongation risk among currently used fluoroquinolones and is contraindicated in patients with known QTc prolongation, uncorrected hypokalemia, or concomitant use of other QT-prolonging drugs. Levofloxacin has intermediate QTc prolongation risk; ciprofloxacin has the lowest risk within the class but is not without effect.1011
CYP1A2 inhibition by ciprofloxacin and, to a greater degree, enoxacin (now withdrawn) is an additional pharmacokinetic drug interaction of clinical relevance. Ciprofloxacin inhibits CYP1A2, the enzyme responsible for hepatic metabolism of theophylline, caffeine, clozapine, and tizanidine. Co-administration of ciprofloxacin with theophylline increases theophylline plasma concentrations by 30 to 50% and can precipitate theophylline toxicity (nausea, seizures, arrhythmias) at previously therapeutic doses; theophylline levels must be monitored and doses reduced preemptively when ciprofloxacin is initiated. The ciprofloxacin-tizanidine combination is contraindicated because the resulting plasma tizanidine increase can cause severe hypotension and sedation. Levofloxacin and moxifloxacin have minimal CYP1A2 inhibitory activity and do not produce clinically significant increases in theophylline concentrations.10
The polyvalent cation interaction is the most common cause of fluoroquinolone treatment failure in the outpatient setting. Patients prescribed ciprofloxacin or levofloxacin should be explicitly instructed: take the antibiotic at least two hours before or six hours after antacids, calcium supplements, iron tablets, or any product containing magnesium, aluminum, or zinc. "Take with a full glass of water" and "avoid dairy" instructions are insufficient alone; the specific timing rule must be communicated. Inpatients on nasogastric tube feeds should have feeds held for one hour before and two hours after fluoroquinolone administration to prevent enteral nutrition-mediated absorption reduction, which is substantial with ciprofloxacin.
Fluoroquinolones carry one of the most extensive collections of serious adverse effects of any antibiotic class, culminating in multiple FDA black box warnings that have substantially changed prescribing practice over the past two decades. Understanding the mechanistic basis of these toxicities, the patient populations at highest risk, and the clinical management strategies is essential for any prescriber who reaches for this drug class.12
Tendinopathy and tendon rupture were the subject of the first fluoroquinolone black box warning, added by the FDA in 2008 and later expanded. Fluoroquinolones impair collagen synthesis and promote collagen degradation by upregulating matrix metalloproteinases (MMPs) and inhibiting tenocyte proliferation through mechanisms that likely involve chelation of magnesium ions required for collagen cross-linking and activation of catabolic signaling pathways in tendon tissue. The Achilles tendon is most frequently affected because of its relatively poor vascular supply and high mechanical load, but tendinopathy can occur at the rotator cuff, hand, biceps, and other tendons. The incidence of tendon rupture is approximately two to four times higher in fluoroquinolone users than in matched controls receiving other antibiotics. Risk is dramatically increased in patients over age 60, in those receiving concurrent systemic corticosteroids (which independently impair tendon repair), and in renal transplant recipients. Tendinopathy can occur within 48 hours of starting therapy, and rupture can occur up to several months after the course is completed. Patients must be counseled to stop the drug immediately and avoid weight-bearing if Achilles pain or swelling develops during or after treatment.1213
Peripheral neuropathy was added to the fluoroquinolone black box warning in 2013 following accumulating postmarketing reports of serious and potentially permanent nerve damage. Patients develop symptoms of sensory, motor, or mixed peripheral neuropathy including pain, burning, tingling, numbness, weakness, and altered proprioception, which may begin within days of starting therapy. The mechanism is incompletely understood but may involve mitochondrial toxicity through inhibition of mitochondrial deoxyribonucleic acid (DNA) replication (topoisomerase II is also present in mitochondria and shares some structural homology with bacterial targets) and oxidative stress. The critical clinical point is that this neuropathy can be irreversible, persisting long after the drug is discontinued. Patients with pre-existing peripheral neuropathy are at particular risk and represent a relative contraindication to fluoroquinolone use. Any new onset of neuropathic symptoms during fluoroquinolone therapy should prompt immediate discontinuation.12
Central nervous system (CNS) adverse effects are among the most common reasons for fluoroquinolone discontinuation and range from mild insomnia, dizziness, and headache to serious events including seizures, toxic psychosis, and exacerbation of myasthenia gravis (MG). CNS excitatory effects are mediated partly through antagonism of gamma-aminobutyric acid type A (GABA-A) receptors and partly through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, producing a net excitatory shift in CNS neurotransmission. The fluoroquinolone black box warning was extended in 2016 to explicitly include CNS effects including psychiatric disturbances such as agitation, anxiety, confusion, depression, hallucinations, and suicidal ideation or behavior. Seizure risk is elevated in patients with pre-existing seizure disorders and in those taking theophylline or nonsteroidal anti-inflammatory drugs (NSAIDs), both of which independently lower seizure threshold. Fluoroquinolone use is contraindicated in patients with known myasthenia gravis because these agents block neuromuscular transmission and can precipitate life-threatening respiratory failure in MG patients.12
The electrocardiographic ventricular repolarization interval (QT) is prolonged by fluoroquinolones through hERG (human ether-a-go-go related gene) potassium channel blockade, reducing the rapid delayed rectifier potassium current (IKr) and prolonging ventricular repolarization, creating risk for torsades de pointes (TdP). Among currently used fluoroquinolones, the rank order for corrected QT interval (QTc) prolongation is moxifloxacin greater than levofloxacin greater than ciprofloxacin, with gatifloxacin (now withdrawn in the United States) and sparfloxacin (also withdrawn) having carried the highest risk in the class historically. Moxifloxacin prolongs the QTc by a mean of approximately 6 milliseconds at therapeutic doses, which is modest in isolation but becomes clinically significant when combined with other QT-prolonging drugs, electrolyte abnormalities (hypokalemia, hypomagnesemia), bradycardia, or underlying cardiac disease. A baseline electrocardiogram (ECG) and electrolyte assessment is prudent before prescribing moxifloxacin in patients with cardiovascular disease or those on other QT-prolonging agents. Spontaneous TdP from fluoroquinolones alone is uncommon but has been reported, particularly in women (who have longer baseline QTc intervals) and in patients with congenital long QT syndrome.11
Dysglycemia is a clinically underappreciated fluoroquinolone adverse effect that can manifest as either hypoglycemia or hyperglycemia, sometimes within the same patient during successive courses. Fluoroquinolones stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels (KATP channels), the same mechanism by which sulfonylureas act, producing hypoglycemia particularly in diabetic patients receiving concurrent sulfonylurea or insulin therapy. Conversely, they can also cause hyperglycemia through mechanisms that include impaired insulin secretion via a different pathway and peripheral insulin resistance. Gatifloxacin, which had the most potent dysglycemic effects in the class, was withdrawn from the US market largely because of severe and sometimes fatal dysglycemia. Among current agents, the risk is greatest with moxifloxacin and lower but still present with levofloxacin and ciprofloxacin. Clinicians should monitor blood glucose closely in diabetic patients receiving fluoroquinolones, particularly when the agent is initiated or discontinued, and should counsel all patients about hypoglycemia symptoms.15
Aortic aneurysm and dissection represent the most recently recognized serious fluoroquinolone adverse effect and were added to the black box warning in 2018. Multiple epidemiological studies and meta-analyses have demonstrated a two- to threefold increased risk of aortic aneurysm or dissection in patients receiving fluoroquinolones compared to matched controls, with the strongest signal in patients with pre-existing aortic aneurysm, hypertension, or Marfan syndrome. The mechanism parallels tendinopathy: fluoroquinolones upregulate MMPs in connective tissue, degrade collagen and elastin in the aortic wall, and impair repair of the extracellular matrix, potentially destabilizing pre-existing aneurysms or accelerating progression of subclinical aortic pathology to dissection. The FDA warning states that fluoroquinolones should be avoided in patients with known aortic aneurysm or at risk for aortic aneurysm and dissection unless no alternative therapy is available. The absolute risk in any individual patient is low, but given the catastrophic consequences of aortic dissection, risk-benefit assessment before prescribing is warranted in high-risk patients.1214
In 2016, the FDA issued a safety communication stating that the serious risks of fluoroquinolones generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated UTI, conditions for which effective and safer alternatives exist. This communication explicitly recommended that fluoroquinolones be reserved for patients who have no other treatment options for these mild infections. The clinical implication is direct: prescribing ciprofloxacin for uncomplicated cystitis in a young woman without risk factors when trimethoprim-sulfamethoxazole, nitrofurantoin, or fosfomycin would be effective is now explicitly discouraged by regulatory guidance, not merely by antimicrobial stewardship preference. When a fluoroquinolone is chosen, the selection should be driven by culture data, indication, and individual patient risk factors for the specific toxicities described above.
Rational fluoroquinolone prescribing requires matching the agent to the infection based on spectrum, pharmacokinetic target attainment at the site of infection, local resistance patterns, and patient-specific contraindications. Simultaneously, resistance to fluoroquinolones has become a critical public health problem, driven by mechanisms that range from chromosomal mutations in the topoisomerase targets to horizontally transferable plasmid-mediated resistance genes that have spread globally across multiple bacterial species.16
Urinary tract infections (UTIs) remain among the most common indications for fluoroquinolones, though stewardship guidance now restricts their use to situations where simpler agents are not appropriate. Ciprofloxacin is the preferred fluoroquinolone for complicated urinary tract infection (UTI) and pyelonephritis caused by susceptible Gram-negative organisms, including Enterobacteriaceae and when Pseudomonas coverage is required. Norfloxacin, though a second-generation agent, was formulated specifically for urinary concentrations and lacks systemic bioavailability adequate for pyelonephritis. Uncomplicated cystitis should be treated with nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX), or fosfomycin in preference to fluoroquinolones unless local resistance rates to those agents exceed 20% or the patient has specific contraindications. This stewardship priority is driven both by preserving fluoroquinolone efficacy and by the FDA 2016 guidance restricting use in uncomplicated infections.612
Respiratory tract infections represent a major domain of fluoroquinolone use, centered on the concept of the respiratory fluoroquinolone, which in current practice refers to levofloxacin and moxifloxacin. The respiratory fluoroquinolones cover the full range of community-acquired pneumonia (CAP) pathogens: Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Moraxella catarrhalis, and atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila), all in a single agent that can be given orally with near-IV bioavailability. This monotherapy convenience advantage is a key reason levofloxacin and moxifloxacin appear in the Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) CAP guidelines as alternatives to beta-lactam plus macrolide combination regimens for outpatient and hospitalized non-ICU patients. Levofloxacin at 750 mg daily is preferred over moxifloxacin for CAP in patients with risk factors for Pseudomonas (structural lung disease, recent broad-spectrum antibiotic use, immunosuppression), whereas moxifloxacin's anaerobic coverage offers a theoretical advantage in aspiration pneumonia when appropriate. Fluoroquinolones should be avoided as monotherapy for CAP in patients at high risk for drug-resistant S. pneumoniae (DRSP) who have received a fluoroquinolone in the prior three months, due to the risk of selecting for target-mutation resistance during that exposure.5
Other major indications for fluoroquinolones include intra-abdominal infections (ciprofloxacin combined with metronidazole as an alternative to beta-lactam-based regimens), skin and soft tissue infections due to susceptible Gram-negative organisms, bone and joint infections (oral ciprofloxacin or levofloxacin for osteomyelitis step-down after parenteral therapy), sexually transmitted infections (azithromycin-resistant gonorrhea, though resistance has significantly limited reliability), and as part of multidrug regimens for Mycobacterium tuberculosis and non-tuberculous mycobacterial infections. Ciprofloxacin is the drug of choice for Bacillus anthracis (anthrax) post-exposure prophylaxis and treatment. Levofloxacin or moxifloxacin are used in second-line tuberculosis (TB) regimens and are among the key drugs for treating multidrug-resistant TB (MDR-TB).5
The most clinically important fluoroquinolone resistance mechanism is target mutation. Resistance most commonly arises through sequential point mutations in the quinolone resistance-determining region (QRDR) of the gyrA and parC genes, which encode the GyrA and ParC subunits of deoxyribonucleic acid (DNA) gyrase and topoisomerase IV respectively. A single QRDR mutation in the primary target gene reduces susceptibility modestly, often raising the minimum inhibitory concentration (MIC) into the intermediate range while the organism may still appear susceptible on standard breakpoint testing. A second mutation in the primary target gene or a mutation in the secondary target confers high-level resistance. This stepwise resistance development means that fluoroquinolones with balanced dual-target activity (such as moxifloxacin) are theoretically superior at suppressing resistance emergence, since simultaneous mutations in both targets must occur together for the organism to survive drug exposure. Fluoroquinolone monotherapy of infections caused by organisms with MICs near the susceptibility breakpoint is particularly prone to select for resistant mutants, emphasizing the importance of achieving area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) ratios well above the threshold for resistance suppression.23
Efflux pump overexpression is a second major chromosomally encoded resistance mechanism. Gram-negative organisms, including P. aeruginosa, E. coli, and Klebsiella species, possess intrinsic multidrug efflux systems of the resistance-nodulation-division (RND) superfamily, including the MexAB-OprM, MexCD-OprJ, and MexXY-OprM systems in Pseudomonas and the AcrAB-TolC system in Enterobacteriaceae. Overexpression of these pumps actively extrudes fluoroquinolones and other antibiotics from the bacterial cell, reducing intracellular drug concentrations below the threshold required for target inhibition. Efflux-mediated resistance often affects multiple drug classes simultaneously, contributing to multidrug-resistant (MDR) phenotypes. Porin loss in Gram-negative outer membranes acts synergistically with efflux overexpression by reducing the rate of drug entry, further limiting intracellular accumulation.3
Plasmid-mediated quinolone resistance (PMQR) represents a paradigm shift in fluoroquinolone resistance epidemiology because it allows resistance determinants to spread horizontally between bacterial species on mobile genetic elements, rather than requiring de novo mutation in each lineage. The first PMQR determinants identified were the qnr genes (quinolone resistance), which encode small pentapeptide repeat proteins that bind directly to DNA gyrase and topoisomerase IV, mimicking DNA structure and competitively protecting the enzymes from fluoroquinolone binding. Individual qnr genes (including qnrA, qnrB, qnrC, qnrD, and qnrS) typically confer only low-level fluoroquinolone resistance on their own, but they reduce susceptibility sufficiently to facilitate selection of additional chromosomal mutations, acting as stepping stones to high-level resistance. Additional PMQR mechanisms include aac(6')-Ib-cr, an aminoglycoside acetyltransferase variant that can also acetylate ciprofloxacin and norfloxacin (reducing their activity), and the efflux pumps OqxAB and QepA, which are encoded on plasmids and contribute additional fluoroquinolone efflux capacity. The global prevalence of PMQR genes in clinical Enterobacteriaceae isolates has grown substantially since their first description, and their presence on plasmids that frequently co-carry beta-lactamase genes including extended-spectrum beta-lactamase (ESBL) genes has made fluoroquinolone resistance a near-universal feature of ESBL-producing organisms.316
Before prescribing any fluoroquinolone, three questions anchor responsible use. First: is there a non-fluoroquinolone agent that is effective for this indication? For uncomplicated cystitis, bronchitis, and sinusitis, the answer is almost always yes. Second: does the patient have a risk factor for serious fluoroquinolone toxicity, including age over 60 with corticosteroid use (tendinopathy), pre-existing peripheral neuropathy, known QTc prolongation or concurrent QT-prolonging drugs, diabetes on sulfonylureas or insulin (dysglycemia), known or suspected aortic aneurysm, or myasthenia gravis? If yes, the risk-benefit calculation shifts significantly. Third: has the patient received a fluoroquinolone in the prior three months? Recent exposure substantially increases the probability of selecting a resistant mutant during current therapy and argues for choosing an alternative class when available.
Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;1354:12–31.
doi:10.1111/nyas.12830Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):1565–1574.
doi:10.1021/bi5000564Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2016;6(9):a025320.
doi:10.1101/cshperspect.a025320Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10.
doi:10.1086/516284Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.
doi:10.1086/511159Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clin Infect Dis. 2011;52(5):e103–e120.
doi:10.1093/cid/ciq257Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 1999;58(Suppl 2):29–36.
doi:10.2165/00003495-199958002-00006Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63(24):2769–2802.
doi:10.2165/00003495-200363240-00008Neuhofel AL, Wilton JH, Victory JM, Hejmanowski LG, Amsden GW. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol. 2002;42(4):461–466.
doi:10.1177/00912700222011391Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S144–S157.
doi:10.1086/428055Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73(4):292–303.
doi:10.1016/S0009-9236(03)00009-2FDA Drug Safety Communication. FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. US Food and Drug Administration; July 26, 2016. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics
van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;324(7349):1306–1307.
doi:10.1136/bmj.324.7349.1306Lee CC, Lee MT, Chen YS, Lee SH, Chen SC, Chang SC. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175(11):1839–1847.
doi:10.1001/jamainternmed.2015.5389Mohr JF, McKinnon PS, Peymann PJ, et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy. 2005;25(10):1303–1309.
doi:10.1592/phco.2005.25.10.1303Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Suppl 2):S120–S126.
doi:10.1086/428052